Indefinite Delivery Contract SPE2DB20D9335

DMS Pharmaceutical Group Inc., a woman-owned small business, was awarded a single-award indefinite delivery contract (IDC) by the Defense Logistics Agency (DLA) valued at up to $4,999,999 through December 31, 2025 under the SPE2DB program. The IDC enables the DLA to issue firm fixed-price delivery orders for DMS Pharmaceutical Group to provide a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military health facilities worldwide.

Under this IDC, the DLA has awarded several delivery orders to DMS Pharmaceutical Group for the supply of products such as contraceptive devices like Nexplanon and Mirena, vaccines like YF-VAX, and other medications and medical supplies. These awards, with no set-aside designations, have ranged from small orders valued at a few hundred dollars up to $30,661 for the delivery of pharmaceutical items to military treatment facilities across the United States. The IDC and associated delivery orders demonstrate DMS Pharmaceutical Group's position as a critical supplier in the federal pharmaceutical supply chain supporting the Department of Defense's medical readiness and healthcare requirements.